572 Biochemie
Refine
Has Fulltext
- yes (95)
Is part of the Bibliography
- yes (95)
Year of publication
Document Type
- Doctoral Thesis (51)
- Journal article (39)
- Master Thesis (2)
- Preprint (2)
- Book article / Book chapter (1)
Keywords
- Transkriptionsfaktor (5)
- DNS-Reparatur (4)
- Ubiquitin (4)
- Regulation (3)
- SMN (3)
- Saccharomyces cerevisiae (3)
- TFIIH (3)
- Thrombozyt (3)
- gene expression (3)
- mass spectrometry (3)
- platelet (3)
- ALS (2)
- Antibody (2)
- Antikörper (2)
- Cancer (2)
- Cytokine (2)
- DNA-Reparatur (2)
- Expression (2)
- Fluoreszenz (2)
- G-Protein gekoppelte Rezeptoren (2)
- Genexpression (2)
- Immunreaktion (2)
- Interleukin 4 (2)
- Messenger-RNP (2)
- Messenger-RNS (2)
- Monoklonaler bispezifischer Antikörper (2)
- Nanopartikel (2)
- Röntgenkristallographie (2)
- Signaltransduktion (2)
- Transkription (2)
- Ubiquitin-Protein-Ligase (2)
- Ubiquitinierung (2)
- Vaccinia-Virus (2)
- apoptosis (2)
- binding (2)
- identification (2)
- immunoprecipitation (2)
- inflammation (2)
- magnetic resonance imaging (2)
- messenger RNA (2)
- mouse models (2)
- neuroblastoma (2)
- pICln (2)
- phosphorylation (2)
- protein (2)
- regulation (2)
- 26S proteasome (1)
- 5-HT1A (1)
- 5-HT2C (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- A2a-R receptor (1)
- AD5 mutation (1)
- AMP-activated protein kinase (AMPK) (1)
- Ackerschmalwand (1)
- Activation (1)
- Adhesion and degranulation promoting adapter protein (1)
- Affinity probe (1)
- Antigen CD40 (1)
- Antigen CD95 (1)
- Antigenrezeptor (1)
- Apoptose (1)
- Aptamer (1)
- Arrestine (1)
- Arzneimitteldesign (1)
- Assembly (1)
- AuNPs (1)
- Aurora-A (1)
- Automation (1)
- B-Zell-Lymphom (1)
- BCMA (1)
- BRAF mutations (1)
- BRCA1 (1)
- BRM (1)
- BRN-3A (1)
- BTB domain (1)
- Baff (1)
- Bakteriorhodopsin (1)
- Bauchspeicheldrüsenkrebs (1)
- Beige adipocytes (1)
- Bierhefe (1)
- Bioanorganische Chemie (1)
- Bioconjugate (1)
- Biologie (1)
- Biomarker (1)
- Bispecific T-cell engager (1)
- Bortezomib (1)
- Brahma (1)
- Breast-cancer (1)
- Bäckerhefe (1)
- C-MYC (1)
- C/EBP (1)
- CGG repeat (1)
- CLIP-seq (1)
- CPG Island (1)
- Cancer Metabolism (1)
- Candida albicans (1)
- Cdc48 (1)
- Chaetomium thermophilum (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Chimeric Antigen Receptor (1)
- Chimärer Antigenrezeptor (1)
- Chinese family (1)
- Cholesterinstoffwechsel (1)
- Chromatin-remodeling complexes (1)
- Chromophor (1)
- Chromosomal Passenger Complex (1)
- Colorectal Cancer (1)
- Combination therapy (1)
- Cyclophosphamide (1)
- Cytoskeleton Chromosomal Passenger Complex Interaction GAR Domain (1)
- DHX30 (1)
- DNA (1)
- DNA Sekundärstruktur (1)
- DNA damage (1)
- DNA methylferase homolog (1)
- DNA repair (1)
- DNA secondary structure (1)
- DNA-binding proteins (1)
- DNS-Bindung (1)
- DNS-Bindungsproteine (1)
- DUB (1)
- Decapping (1)
- Deubiquitination (1)
- Deuteriumaustausch (1)
- Dickdarmkrebs (1)
- Differentiation (1)
- Dihydroisochinolinderivate (1)
- Dihydroisochinolinonderivate (1)
- Diphenylether (1)
- Disease (1)
- Distinct (1)
- Drosophila melanogaster (1)
- Drug delivery platform (1)
- Drug delivery system (DDS) (1)
- Dualstere Liganden (1)
- Dualsteric Ligands (1)
- E2 (1)
- Echinococcus (1)
- Enzym (1)
- Excitatory/inhibitory imbalance (1)
- Exons (1)
- FMR1 (1)
- FMR2 (1)
- FMRP (1)
- FRET (1)
- FXR1 (1)
- FXR2 (1)
- Factor gene PRPF31 (1)
- FcgR (1)
- Fettsäurestoffwechsel (1)
- Fluorescence microscopy (1)
- Fluoreszenz-Resonanz-Energie-Transfer (1)
- Fluoreszenzmikroskopie (1)
- Fragiles-X-Syndrom (1)
- Fuchsbandwurm (1)
- G3BP (1)
- GAS2L3 (1)
- GLV-1H68 (1)
- Ganzkörperbestrahlung (1)
- Gen BRCA 1 (1)
- Gen notch (1)
- Gene Expression (1)
- Gene regulation (1)
- General Transcription Factor II H (1)
- Genes (1)
- Genexpressionsmaschinerie (1)
- Genome Instability (1)
- Genregulation (1)
- Gephyrin (1)
- Gold Nanoparticles (1)
- HUWE1 (1)
- Halobacterium halobium (1)
- Helikasen (1)
- Hemibodies (1)
- Hemibody (1)
- Hey Proteine (1)
- Hey proteins (1)
- Hitzeschockproteine (1)
- Hitzestress (1)
- Homebox gene (1)
- Hsc70 (1)
- Human Sodium/Iodide symporter (1)
- IN-VIVO (1)
- Ifn-gamma (1)
- In-Vivo (1)
- In-vivo (1)
- Induzierte pluripotente Stammzelle (1)
- Inhibitor (1)
- Inhibitorische Synapse (1)
- Inhibitory synapse (1)
- Insulinsekretion (1)
- Interferon <alpha-2a-> (1)
- KSR1 (1)
- Knochenmark (1)
- Knochenmarktransplantation (1)
- Kolorektales Karzinom (1)
- Konjugation (1)
- Kontrollierte Wirkstofffreisetzung (1)
- Krebs <Medizin> (1)
- Kristallstruktur (1)
- LCK (1)
- Library Screening (1)
- Lipidumbau (1)
- Lung cancer (1)
- Lung squamous cancer cells (1)
- MAP-Kinase (1)
- MAPK (1)
- MDSCs (1)
- MIZ1 (1)
- MYCN (1)
- Macromolecular Assembly (1)
- Macromolecular Crystallography (1)
- Mechanismus (1)
- Megakaryocyte (1)
- Megakaryozyt (1)
- Metabolismus (1)
- Mevalonate Pathway (1)
- Modifikation (1)
- Molecular Chaperone (1)
- Molekulargenetik (1)
- MscS (1)
- Multidrug-Resistenz (1)
- Multiple Myeloma (1)
- Multiples Myelom (1)
- Muscarinrezeptor (1)
- Mutations (1)
- Myc (1)
- N-MYC (1)
- N-Myc (1)
- NA+/I-symporter (1)
- NEDMIAL (1)
- NFkB-Signalling (1)
- NO (1)
- NPY (1)
- Nanodiamant (1)
- Nanodiamond (1)
- Nanoparticles (1)
- Nekroptose (1)
- Nekrose (1)
- Neural precursor cells (1)
- Neuroblastom (1)
- Neuroblastoma (1)
- Neurodevelopmental diseases (1)
- Neuropeptide Hormone (1)
- Neuropeptidhormon (1)
- Notch Signalweg (1)
- Notch signalling (1)
- Nucleinsäuren (1)
- Nucleosidanaloga (1)
- Nucleoside (1)
- Nucleotide excision repair (1)
- Nude-mice (1)
- Nukleotid-Exzisions-Reparatur (1)
- Oligomerisation (1)
- OmoMYC (1)
- Oncolysis (1)
- Oncolytic vaccinia virus (1)
- Onkogen (1)
- Onkolyse (1)
- Opiatrezeptor (1)
- Opioide (1)
- P53 (1)
- P97 (1)
- PAR-CLIP (1)
- PDXP inhibitors (1)
- PGAS (1)
- PRPF31 (1)
- Partial Agonists (1)
- Partialagonismus (1)
- Particle analytics (1)
- Partikelanalytik (1)
- Pathway (1)
- Peptide (1)
- Peptidsynthese (1)
- Pharmakodynamik (1)
- Platelet (1)
- Pockenviren (1)
- Polo-like kinase 1 (1)
- Polyethylenglykole (1)
- Polyglycerol (1)
- Polymere (1)
- Polypeptidketten bindende Proteine (1)
- Poxviridae (1)
- Progenitor cells (1)
- Protease-sensitive release (1)
- Proteasom (1)
- Proteasome (1)
- Protein (1)
- Protein kinase D1 (PKD1) (1)
- Protein kinase D3 (PKD3) (1)
- Proteinbiosynthese (1)
- Protonenpumpe (1)
- Purpurmembran (1)
- Quadruplex-DNS (1)
- RIP3 (1)
- RNA (1)
- RNA binding protein (1)
- RNA binding proteins (1)
- RNA helicase (1)
- RNA interference (1)
- RNA metabolism (1)
- RNA splicing (1)
- RNA-Polymerase (1)
- RNA-polymerase-II (1)
- RNA-seq (1)
- RNS (1)
- RP11 (1)
- RecQ helicase (1)
- Rekonstitution (1)
- Reporter Cells (1)
- Reporter gene (1)
- Reporterzellen (1)
- Retinitis pigmentosa (RP) (1)
- Retinoic acid (1)
- Rezeptorpharmakologie (1)
- Rothmund-Thomson-Syndrome (1)
- SM proteins (1)
- SP117 mutation (1)
- SPION (1)
- Salmonella enterica (1)
- Schizophrenie (1)
- Schizosaccharomyces pombe (1)
- Screening (1)
- SdsR (1)
- Sekundärstruktur (1)
- Signalweg (1)
- Site-specific protein conjugation (1)
- Small nuclear RNP (1)
- Solid-phase peptide synthesis (1)
- Spleißosom (1)
- Squamous cell carcinoma (1)
- Ssl1 (1)
- Stammzelle (1)
- Structural Biology (1)
- Struktur (1)
- Strukturbiologie (1)
- Strumpellin (1)
- Subunit (1)
- T cells (1)
- T-Lymphozyt (1)
- T-cell engager (1)
- T-lymphocytes (1)
- TDRD3 (1)
- TFIIIC (1)
- TIAR (1)
- TNF (1)
- TOP mRNA (1)
- TOP3b (1)
- TRAF2 (1)
- TRI-SNRNP (1)
- TRNA(ASP) (1)
- TTF complex (1)
- TWEAK (1)
- Targeted drug delivery (1)
- Targeted therapies (1)
- Terminal Oligopyrimidine Tract (1)
- Tfb4 (1)
- Therapy (1)
- Thermotoleranz (1)
- Thiolase (1)
- Tissue Engineering (1)
- Transcription (1)
- Transcription factor (1)
- Transgenic zebrafish (1)
- Transkription <Genetik> (1)
- Translation <Genetik> (1)
- Translationsinitiation (1)
- Translationskontrolle (1)
- Transporter (1)
- Triglyceride (1)
- Trithorax (1)
- Tritiumaustausch (1)
- Tuberkulose (1)
- Tumor (1)
- Tumor models (1)
- Tumour (1)
- U snRNPs (1)
- UBE2S (1)
- USP (1)
- USP28 (1)
- Ubiquitin-conjugating enzyme (1)
- VACV (1)
- Vaccinia virus (1)
- Verweildauer (1)
- Virotherapie (1)
- Virotherapy (1)
- WASH complex (1)
- X-ray crystallography (1)
- YnaI (1)
- Zellteilung (1)
- Zellzyklus (1)
- Zink-Finger-Proteine (1)
- adaptive immunity (1)
- adsorption (1)
- alpha-IIb beta-3 (1)
- animal behavior (1)
- anti-sigma factor (1)
- antigen expression (1)
- antitumor immune response (1)
- antiviral immunity (1)
- aquired resistance (1)
- arginine (1)
- arterial elasticity (1)
- ascites (1)
- assembly chaperone (1)
- atherosclerosis (1)
- autoantibodies (1)
- autophagy (1)
- bacterial fatty-acid biosynthesis (1)
- biased agonism (1)
- binding mode (1)
- biochemistry (1)
- bispecific (1)
- bispezifisch (1)
- blood (1)
- bone marrow (1)
- breast cancer (1)
- cancer microenvironment (1)
- cancer treatment (1)
- cations (1)
- cell carcinoma (1)
- cholesterol (1)
- circadian rhythms (1)
- coexpression (1)
- cohesin (1)
- colorectal cancer (1)
- coloteral cancer (1)
- comparative genomic hybridization (1)
- complexity (1)
- cyanelle (1)
- cytokinin (1)
- cytokinin kinetin (1)
- cytoskeleton (1)
- deep sequencing (1)
- delipidation (1)
- density gradient centrifugation (1)
- deubiquitinase (1)
- diabetes (1)
- diacylglycerol (DAG) (1)
- differential centrifugation (1)
- diversity (1)
- domain (1)
- dominant-negative (1)
- down regulation (1)
- drospophila (1)
- dual targeting (1)
- ectopic release (1)
- electron cryomicroscopy (1)
- electron microscopy (1)
- embryos (1)
- endosomal trafficking (1)
- enoyl-ACP reductase (1)
- enzyme (1)
- eukaryotic gene expression (1)
- evolutionary genetics (1)
- expression (1)
- extracellular domain (1)
- family (1)
- fluorescence (1)
- fluorescence imaging (1)
- fluorescence microscopy (1)
- fraxe mental retardation (1)
- genes (1)
- genome integrity (1)
- genome stability (1)
- genome-wide analysis (1)
- genomics (1)
- glycerol (1)
- glycine receptor (1)
- glycosylation (1)
- granulophagy (1)
- granulostasis (1)
- haploinsufficiency (1)
- histology (1)
- homeostasis (1)
- humanized tumor (1)
- hyperexpression techniques (1)
- iNOS (1)
- iPSCs (1)
- in vitro (1)
- in vivo imaging (1)
- in vivo toxicity (1)
- in-vitro (1)
- in-vivo (1)
- inhibition (1)
- inhibitor residence time (1)
- innate immune system (1)
- innate immunity (1)
- insulin (1)
- interaction networks (1)
- label-free quantification (1)
- limiting dilution cloning (1)
- lipid bilayer (1)
- lipid remodeling (1)
- liver (1)
- living cells (1)
- lymph nodes (1)
- mRNA metabolism (1)
- macrophages (1)
- males (1)
- malignant melanoma (1)
- mechanism (1)
- mechanosensing (1)
- mechanosensitive channels (1)
- melanoma (1)
- membrane potential (1)
- membrane proteins (1)
- membrane structures (1)
- metabolism (1)
- metastatic tumors (1)
- miR-181 (1)
- modulatory effects (1)
- molecular evolution (1)
- molecular mass (1)
- monoclonal stable cell (1)
- motor-neuron protein (1)
- mouse model (1)
- mutation (1)
- myeloablation (1)
- myeloma (1)
- ncuCyte\(^®\)S3 (1)
- neural crest factors (1)
- neurons (1)
- oligomerization (1)
- oncogene-induced senescence (1)
- oncolytic virus therapy (1)
- oncolytic viruses (1)
- organellar mapping (1)
- p34 (1)
- p44 (1)
- p97/VCP (1)
- pancreas (1)
- partial purification (1)
- peptide (1)
- permutation (1)
- peroxisome purification (1)
- phase transition (1)
- photooxidative stress (1)
- photosynthesis genes (1)
- plant hormones (1)
- plant-microbe interaction (1)
- poly(2-ethyl-2-oxazoline) (1)
- posttranscriptional gene regulation (1)
- prognostic biomarkers (1)
- prognostic relevance (1)
- promoter invasion (1)
- prostate cancer (1)
- protein argentine methyltranserase (1)
- protein domains (1)
- protein interactions (1)
- protein localization (1)
- protein subunit (1)
- protein synthesis (1)
- protein-lipid interactions (1)
- pulse wave velocity (1)
- pyridoxal phosphatase (PDXP) (1)
- quality control (1)
- quanititative proteomics (1)
- red blood cells (1)
- regulatory RNA (1)
- replication (1)
- rhodobacter sphaeroides (1)
- ribonuclease-P (1)
- ribosome (1)
- ribosome profiling (1)
- rod degeneration (1)
- sRNA (1)
- schizophrenia (1)
- separation (1)
- sequence (1)
- signaling (1)
- signalling (1)
- singlet oxygen stress (1)
- small RNA (1)
- snRNPs (1)
- spatial proteomics (1)
- spliceosomes (1)
- splicing defect (1)
- splicing factor (1)
- stem cells (1)
- structural mechanism (1)
- structure-based drug design (1)
- subcutaneous human tumors (1)
- systems biology (1)
- thermotolerance (1)
- thrombopoiesis (1)
- tissue microarray (1)
- toxins (1)
- transcription factors (1)
- transcription/replication conflicts (1)
- translation initiation (1)
- translational regulation (1)
- triple in situ hybridization (1)
- trispecific (1)
- tumors (1)
- tumourigenesis (1)
- tyrosine phosphorylation (1)
- ubiquitin chain formation (1)
- ubiquitin linkage specificity (1)
- ubiquitin recognition (1)
- ubiquitination (1)
- vitamin B6 (1)
- wall shear stress (1)
- zebrafish (1)
- zinc-finger (1)
- ΔNp63 (1)
- β cell (1)
- β3 adrenergic receptor (ADRB3) (1)
Institute
- Graduate School of Life Sciences (35)
- Lehrstuhl für Biochemie (32)
- Theodor-Boveri-Institut für Biowissenschaften (22)
- Rudolf-Virchow-Zentrum (13)
- Institut für Molekulare Infektionsbiologie (7)
- Institut für Experimentelle Biomedizin (4)
- Fakultät für Chemie und Pharmazie (3)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Medizinische Klinik und Poliklinik II (3)
- Fakultät für Biologie (2)
Schriftenreihe
Sonstige beteiligte Institutionen
ResearcherID
The number of fungal infections is rising in Germany and worldwide. These infections are mainly caused by the opportunistic fungal pathogen C. albicans, which especially harms immunocompromised people. With increasing numbers of fungal infections, more frequent and longer lasting treatments are necessary and lead to an increase of drug resistances, for example against the clinically applied therapeutic fluconazole. Drug resistance in C. albicans can be mediated by the Multidrug resistance pump 1 (Mdr1), a membrane transporter belonging to the major facilitator family. However, Mdr1-mediated fluconazole drug resistance is caused by the pump’s regulator, the transcription factor Mrr1 (Multidrug resistance regulator 1). It was shown that Mrr1 is hyperactive without stimulation or further activation in resistant strains which is due to so called gain of function mutations in the MRR1 gene.
To understand the mechanism that lays behind this constitutive activity of Mrr1, the transcription factor should be structurally and functionally (in vitro) characterized which could provide a basis for successful drug development to target Mdr1-mediated drug resistance caused by Mrr1. Therefore, the entire 1108 amino acid protein was successfully expressed in Escherichia coli. However, further purification was compromised as the protein tended to form aggregates, unsuitable for crystallization trials or further characterization experiments. Expression trials in the eukaryote Pichia pastoris neither yielded full length nor truncated Mrr1 protein. In order to overcome the aggregation problem, a shortened variant, missing the N-terminal 249 amino acids named Mrr1 ‘250’, was successfully expressed in E. coli and could be purified without aggregation. Similar to the wild type Mrr1 ‘250’, selected gain of function variants were successfully cloned, expressed and purified with varying yields and with varying purity. The Mrr1 `250’ construct contains most of the described regulatory domains of Mrr1. It was used for crystallization and an initial comparative analysis between the wild type protein and the variants. The proposed dimeric form of the transcription factor, necessary for DNA binding, could be verified for both, the wild type and the mutant proteins. Secondary structure analysis by circular dichroism measurements revealed no significant differences in the overall fold of the wild type and variant proteins. In vitro, the gain of function variants seem to be less stable compared to the wild type protein, as they were more prone to degradation. Whether this observation holds true for the full length protein’s stability in vitro and in vivo remains to be determined. The crystallization experiments, performed with the Mrr1 ‘250’ constructs, led to few small needle shaped or cubic crystals, which did not diffract very well and were hardly reproducible. Therefore no structural information of the transcription factor could be gained so far.
Infections with M. tuberculosis, the causative agent of tuberculosis, are the leading cause of mortality among bacterial diseases. Especially long treatment times, an increasing number of resistant strains and the prevalence of for decades persisting bacteria create the necessity for new drugs against this disease. The cholesterol import and metabolism pathways were discovered as promising new targets and interestingly they seem to play an important role for the chronic stage of the tuberculosis infection and for persisting bacteria.
In this thesis, the 3-ketoacyl-CoA thiolase FadA5 from M. tuberculosis was characterized and the potential for specifically targeting this enzyme was investigated. FadA5 catalyzes the last step of the β-oxidation reaction in the side-chain degradation pathway of cholesterol. We solved the three dimensional structure of this enzyme by X-ray crystallography and obtained two different apo structures and three structures in complex with acetyl-CoA, CoA and a hydrolyzed steroid-CoA, which is the natural product of FadA5. Analysis of the FadA5 apo structures revealed a typical thiolase fold as it is common for biosynthetic and degradative enzymes of this class for one of the structures. The second apo structure showed deviations from the typical thiolase fold. All obtained structures show the enzyme as a dimer, which is consistent with the observed dimer formation in solution. Thus the dimer is likely to be the catalytically active form of the enzyme. Besides the characteristic structural fold, the catalytic triad, comprising two cysteines and one histidine, as well as the typical coenzyme A binding site of enzymes belonging to the thiolase class could be identified. The two obtained apo structures differed significantly from each other. One apo structure is in agreement with the characteristic thiolase fold and the well-known dimer interface could be identified in our structure. The same characteristics were observed in all complex structures. In contrast, the second apo structure followed the thiolase fold only partially. One subdomain, spanning 30 amino acids, was in a different orientation. This reorientation was caused by the formation of two disulfide bonds, including the active site cysteines, which rendered the enzyme inactive. The disulfide bonds together with the resulting domain swap still permitted dimer formation, yet with a significantly shifted dimer interface. The comparison of the apo structures together with the preliminary activity analysis performed by our collaborator suggest, that FadA5 can be inactivated by oxidation and reactivated by reduction. If this redox switch is of biological importance requires further evaluation, however, this would be the first reported example of a bacterial thiolase employing redox regulation.
Our obtained complex structures represent different stages of the thiolase reaction cycle. In some complex structures, FadA5 was found to be acetylated at the catalytic cysteine and it was in complex with acetyl-CoA or CoA. These structures, together with the FadA5 structure in complex with a hydrolyzed steroid-CoA, revealed important insights into enzyme dynamics upon ligand binding and release. The steroid-bound structure is as yet a unique example of a thiolase enzyme interacting with a complex ligand. The characterized enzyme was used as platform for modeling studies and for comparison with human thiolases. These studies permitted initial conclusions regarding the specific targetability of FadA5 as a drug target against M. tuberculosis infection, taking the closely related human enzymes into account. Additional analyses led to the proposal of a specific lead compound based on the steroid and ligand interactions within the active site of FadA5.
Background: The weight that gene copy number plays in transcription remains controversial; although in specific cases gene expression correlates with copy number, the relationship cannot be inferred at the global level. We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number.
Results: Functional interpretation of 3,030 transcripts concordantly expressed (Pearson's correlation coefficient p-value < 0.05) by CMs and TMs confirmed an enrichment of functions crucial to oncogenesis. Among them, 968 were expressed according to the transcriptional efficiency predicted by copy number analysis (Pearson's correlation coefficient p-value < 0.05). We named these genes, "genomic delegates" as they represent at the transcriptional level the genetic footprint of individual cancers. We then tested whether the genes could categorize 112 melanoma metastases. Two divergent phenotypes were observed: one with prevalent expression of cancer testis antigens, enhanced cyclin activity, WNT signaling, and a Th17 immune phenotype (Class A). This phenotype expressed, therefore, transcripts previously associated to more aggressive cancer. The second class (B) prevalently expressed genes associated with melanoma signaling including MITF, melanoma differentiation antigens, and displayed a Th1 immune phenotype associated with better prognosis and likelihood to respond to immunotherapy. An intermediate third class (C) was further identified. The three phenotypes were confirmed by unsupervised principal component analysis.
Conclusions: This study suggests that clinically relevant phenotypes of melanoma can be retraced to stable oncogenic properties of cancer cells linked to their genetic back bone, and offers a roadmap for uncovering novel targets for tailored anti-cancer therapy.
RNase P processes the 5'-end of tRNAs. An essential catalytic RNA has been demonstrated in Bacteria, Archaea and the nuclei of most eukaryotes; an organism-specific number of proteins complement the holoenzyme. Nuclear RNase P from yeast and humans is well understood and contains an RNA, similar to the sister enzyme RNase MRP. In contrast, no protein subunits have yet been identified in the plant enzymes, and the presence of a nucleic acid in RNase P is still enigmatic. We have thus set out to identify and characterize the subunits of these enzymes in two plant model systems. Expression of the two known Arabidopsis MRP RNA genes in vivo was verified. The first wheat MRP RNA sequences are presented, leading to improved structure models for plant MRP RNAs. A novel mRNA encoding the central RNase P/MRP protein Pop1p was identified in Arabidopsis, suggesting the expression of distinct protein variants from this gene in vivo. Pop1p-specific antibodies precipitate RNase P activity and MRP RNAs from wheat extracts. Our results provide evidence that in plants, Pop1p is associated with MRP RNAs and with the catalytic subunit of RNase P, either separately or in a single large complex.
GAS2L3 was identified recently as a target gene of the DREAM complex (Reichert et al., 2010; Wolter et al., 2012). It was shown that GAS2L3 is expressed in a cell cycle specific manner and that depletion of the protein leads to defects in cytokinesis and genomic instability (Wolter et al., 2012).
Major aim of this thesis was, to further characterize the biochemical properties and physiological function of GAS2L3.
By in vitro co-sedimentation and bundling assays, GAS2L3 was identified as a cytoskeleton associated protein which bundles, binds and crosslinks F-actin and MTs. GST pulldown assays and co-immunoprecipitation experiments revealed that GAS2L3 interacts in vitro and in vivo with the chromosomal passenger complex (CPC), a very important regulator of mitosis and cytokinesis, and that the interaction is mediated by the GAR domain of GAS2L3 and the C-terminal part of Borealin and the N-terminal part of Survivin. Kinase assays showed that GAS2L3 is not a substrate of the CPC but is strongly phosphorylated by CDK1 in vitro. Depletion of GAS2L3 by shRNA influenced protein stability and activity of the CPC. However pharmacological studies showed that the decreased CPC activity is not responsible for the observed cytokinesis defects upon GAS2L3 depletion. Immunofluorescence experiments revealed that GAS2L3 is localized to the constriction zone by the CPC in a GAR dependent manner and that the GAR domain is important for proper protein function.
New interacting proteins of GAS2L3 were identified by stable isotope labelling by amino acids in cell culture (SILAC) in combination with tandem affinity purification and subsequent mass spectrometrical analysis. Co-immunoprecipitation experiments further confirmed the obtained mass spectrometrical data.
To address the physiological function of GAS2L3 in vivo, a conditional and a non-conditional knockout mouse strain was established. The non-conditional mouse strain showed a highly increased mortality rate before weaning age probably due to heart failure. The physiological function of GAS2L3 in vivo as well as the exact reason for the observed heart phenotype is not known at the moment.
Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes
(2015)
Fragile X syndrome (FXS) is mostly caused by a CGG triplet expansion in the fragile X mental retardation 1 gene (FMR1). Up to 60% of affected males fulfill criteria for autism spectrum disorder (ASD), making FXS the most frequent monogenetic cause of syndromic ASD. It is unknown, however, whether normal variants (independent of mutations) in the fragile X gene family (FMR1, FXR1, FXR2) and in FMR2 modulate autistic features. Here, we report an accumulation model of 8 SNPs in these genes, associated with autistic traits in a discovery sample of male patients with schizophrenia (N = 692) and three independent replicate samples: patients with schizophrenia (N = 626), patients with other psychiatric diagnoses (N = 111) and a general population sample (N = 2005). For first mechanistic insight, we contrasted microRNA expression in peripheral blood mononuclear cells of selected extreme group subjects with high-versus low-risk constellation regarding the accumulation model. Thereby, the brain-expressed miR-181 species emerged as potential "umbrella regulator", with several seed matches across the fragile X gene family and FMR2. To conclude, normal variation in these genes contributes to the continuum of autistic phenotypes.
Agrobacterium species are capable of interkingdom gene transfer between bacteria and plants. The genome of Agrobacterium tumefaciens consists of a circular and a linear chromosome, the At-plasmid and the Ti-plasmid, which harbors bacterial virulence genes required for tumor formation in plants. Little is known about promoter sequences and the small RNA (sRNA) repertoire of this and other α-proteobacteria. We used a differential RNA sequencing (dRNA-seq) approach to map transcriptional start sites of 388 annotated genes and operons. In addition, a total number of 228 sRNAs was revealed from all four Agrobacterium replicons. Twenty-two of these were confirmed by independent RNA gel blot analysis and several sRNAs were differentially expressed in response to growth media, growth phase, temperature or pH. One sRNA from the Ti-plasmid was massively induced under virulence conditions. The presence of 76 cis-antisense sRNAs, two of them on the reverse strand of virulence genes, suggests considerable antisense transcription in Agrobacterium. The information gained from this study provides a valuable reservoir for an in-depth understanding of sRNA-mediated regulation of the complex physiology and infection process of Agrobacterium.
Multiple fluorescence in situ hybridization is the method of choice for studies aimed at determining simultaneous production of signal transduction molecules and neuromodulators in neurons. In our analyses of the monoamine receptor mRNA expression of peptidergic neurons in the rat telencephalon, double tyramide-signal-amplified fluorescence in situ hybridization delivered satisfactory results for coexpression analysis of neuropeptide Y (NPY) and serotonin receptor 2C (5-HT2C) mRNA, a receptor subtype expressed at high-to-moderate abundance in the regions analyzed. However, expression of 5-HT1A mRNA, which is expressed at comparatively low abundance in many telencephalic areas, could not be unequivocally identified in NPY mRNA-reactive neurons due to high background and poor signal-to-noise ratio in fluorescent receptor mRNA detections. Parallel chromogenic in situ hybridization provided clear labeling for 5-HT1A mRNA and additionally offered the possibility to monitor the chromogen deposition at regular time intervals to determine the optimal signal-to-noise ratio. We first developed a double labeling protocol combining fluorescence and chromogenic in situ hybridization and subsequently expanded this variation to combine double fluorescence and chromogenic in situ hybridization for triple labelings. With this method, we documented expression of 5-HT2C and/or 5-HT1A in subpopulations of telencephalic NPY-producing neurons. The method developed in the present study appears suitable for conventional light and fluorescence microscopy, combines advantages of fluorescence and chromogenic in situ hybridization protocols and thus provides a reliable non-radioactive alternative to previously published multiple labeling methods for coexpression analyses in which one mRNA species requires highly sensitive detection.
Background
Oncolytic virotherapy of tumors is an up-coming, promising therapeutic modality of cancer therapy. Unfortunately, non-invasive techniques to evaluate the inflammatory host response to treatment are rare. Here, we evaluate \(^{19}\)F magnetic resonance imaging (MRI) which enables the non-invasive visualization of inflammatory processes in pathological conditions by the use of perfluorocarbon nanoemulsions (PFC) for monitoring of oncolytic virotherapy.
Methodology/Principal Findings
The Vaccinia virus strain GLV-1h68 was used as an oncolytic agent for the treatment of different tumor models. Systemic application of PFC emulsions followed by \(^1H\)/\(^{19}\)F MRI of mock-infected and GLV-1h68-infected tumor-bearing mice revealed a significant accumulation of the \(^{19}\)F signal in the tumor rim of virus-treated mice. Histological examination of tumors confirmed a similar spatial distribution of the \(^{19}\)F signal hot spots and \(CD68^+\)-macrophages. Thereby, the \(CD68^+\)-macrophages encapsulate the GFP-positive viral infection foci. In multiple tumor models, we specifically visualized early inflammatory cell recruitment in Vaccinia virus colonized tumors. Furthermore, we documented that the \(^{19}\)F signal correlated with the extent of viral spreading within tumors.
Conclusions/Significance
These results suggest \(^{19}\)F MRI as a non-invasive methodology to document the tumor-associated host immune response as well as the extent of intratumoral viral replication. Thus, \(^{19}\)F MRI represents a new platform to non-invasively investigate the role of the host immune response for therapeutic outcome of oncolytic virotherapy and individual patient response.
Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus, free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intra-peritoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids of patients with metastatic disease.
Integrative "Omics"-Approach Discovers Dynamic and Regulatory Features of Bacterial Stress Responses
(2013)
Bacteria constantly face stress conditions and therefore mount specific responses to ensure adaptation and survival. Stress responses were believed to be predominantly regulated at the transcriptional level. In the phototrophic bacterium Rhodobacter sphaeroides the response to singlet oxygen is initiated by alternative sigma factors. Further adaptive mechanisms include post-transcriptional and post-translational events, which have to be considered to gain a deeper understanding of how sophisticated regulation networks operate. To address this issue, we integrated three layers of regulation: (1) total mRNA levels at different time-points revealed dynamics of the transcriptome, (2) mRNAs in polysome fractions reported on translational regulation (translatome), and (3) SILAC-based mass spectrometry was used to quantify protein abundances (proteome). The singlet oxygen stress response exhibited highly dynamic features regarding short-term effects and late adaptation, which could in part be assigned to the sigma factors RpoE and RpoH2 generating distinct expression kinetics of corresponding regulons. The occurrence of polar expression patterns of genes within stress-inducible operons pointed to an alternative of dynamic fine-tuning upon stress. In addition to transcriptional activation, we observed significant induction of genes at the post-transcriptional level (translatome), which identified new putative regulators and assigned genes of quorum sensing to the singlet oxygen stress response. Intriguingly, the SILAC approach explored the stress-dependent decline of photosynthetic proteins, but also identified 19 new open reading frames, which were partly validated by RNA-seq. We propose that comparative approaches as presented here will help to create multi-layered expression maps on the system level ("expressome"). Finally, intense mass spectrometry combined with RNA-seq might be the future tool of choice to re-annotate genomes in various organisms and will help to understand how they adapt to alternating conditions.
Although the DNA methyltransferase 2 family is highly conserved during evolution and recent reports suggested a dual specificity with stronger activity on transfer RNA (tRNA) than DNA substrates, the biological function is still obscure. We show that the Dictyostelium discoideum Dnmt2-homologue DnmA is an active tRNA methyltransferase that modifies C38 in \(tRNA^{Asp(GUC)}\) in vitro and in vivo. By an ultraviolet-crosslinking and immunoprecipitation approach, we identified further DnmA targets. This revealed specific tRNA fragments bound by the enzyme and identified \(tRNA^{Glu(CUC/UUC)}\) and \(tRNA^{Gly(GCC)}\) as new but weaker substrates for both human Dnmt2 and DnmA in vitro but apparently not in vivo. Dnmt2 enzymes form transient covalent complexes with their substrates. The dynamics of complex formation and complex resolution reflect methylation efficiency in vitro. Quantitative PCR analyses revealed alterations in dnmA expression during development, cell cycle and in response to temperature stress. However, dnmA expression only partially correlated with tRNA methylation in vivo. Strikingly, dnmA expression in the laboratory strain AX2 was significantly lower than in the NC4 parent strain. As expression levels and binding of DnmA to a target in vivo are apparently not necessarily accompanied by methylation, we propose an additional biological function of DnmA apart from methylation.
Pigment cells and neuronal cells both are derived from the neural crest. Here, we describe the Pit-Oct-Unc (POU) domain transcription factor Brn3a, normally involved in neuronal development, to be frequently expressed in melanoma, but not in melanocytes and nevi. RNAi-mediated silencing of Brn3a strongly reduced the viability of melanoma cell lines and decreased tumour growth in vivo. In melanoma cell lines, inhibition of Brn3a caused DNA double-strand breaks as evidenced by Mre11/Rad50-containing nuclear foci. Activated DNA damage signalling caused stabilization of the tumour suppressor p53, which resulted in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in primary melanocytes and fibroblasts, anchorage-independent growth was increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth in vivo. Furthermore, Brn3a cooperated with proliferation pathways such as oncogenic BRAF, by reducing oncogene-induced senescence in non-malignant melanocytes. Together, these results identify Brn3a as a new factor in melanoma that is essential for melanoma cell survival and that promotes melanocytic transformation and tumourigenesis.
Plant hormones involving salicylic acid (SA), jasmonic acid (JA), ethylene (Et), and auxin, gibberellins, and abscisic acid (ABA) are known to regulate host immune responses. However, plant hormone cytokinin has the potential to modulate defense signaling including SA and JA. It promotes plant pathogen and herbivore resistance; underlying mechanisms are still unknown. Using systems biology approaches, we unravel hub points of immune interaction mediated by cytokinin signaling in Arabidopsis. High-confidence Arabidopsis protein-protein interactions (PPI) are coupled to changes in cytokinin-mediated gene expression. Nodes of the cellular interactome that are enriched in immune functions also reconstitute sub-networks. Topological analyses and their specific immunological relevance lead to the identification of functional hubs in cellular interactome. We discuss our identified immune hubs in light of an emerging model of cytokinin-mediated immune defense against pathogen infection in plants.
The Hey protein family, comprising Hey1, Hey2 and HeyL in mammals, conveys Notch signals in many cell types. The helix-loop-helix (HLH) domain as well as the Orange domain, mediate homo- and heterodimerization of these transcription factors. Although distinct interaction partners have been identified so far, their physiological relevance for Hey functions is still largely unclear. Using a tandem affinity purification approach and mass spectrometry analysis we identified members of an ubiquitin E3-ligase complex consisting of FBXO45, PAM and SKP1 as novel Hey1 associated proteins. There is a direct interaction between Hey1 and FBXO45, whereas FBXO45 is needed to mediate indirect Hey1 binding to SKP1. Expression of Hey1 induces translocation of FBXO45 and PAM into the nucleus. Hey1 is a short-lived protein that is degraded by the proteasome, but there is no evidence for FBXO45-dependent ubiquitination of Hey1. On the contrary, Hey1 mediated nuclear translocation of FBXO45 and its associated ubiquitin ligase complex may extend its spectrum to additional nuclear targets triggering their ubiquitination. This suggests a novel mechanism of action for Hey bHLH factors.
Escherichia coli α-hemolysin (HlyA) is a pore-forming protein of 110 kDa belonging to the family of RTX toxins. A hydrophobic region between the amino acid residues 238 and 410 in the N-terminal half of HlyA has previously been suggested to form hydrophobic and/or amphipathic α-helices and has been shown to be important for hemolytic activity and pore formation in biological and artificial membranes. The structure of the HlyA transmembrane channel is, however, largely unknown. For further investigation of the channel structure, we deleted in HlyA different stretches of amino acids that could form amphipathic β-strands according to secondary structure predictions (residues 71–110, 158–167, 180–203, and 264–286). These deletions resulted in HlyA mutants with strongly reduced hemolytic activity. Lipid bilayer measurements demonstrated that HlyAΔ71–110 and HlyAΔ264–286 formed channels with much smaller single-channel conductance than wildtype HlyA, whereas their channel-forming activity was virtually as high as that of the wildtype toxin. HlyAΔ158–167 and HlyAΔ180–203 were unable to form defined channels in lipid bilayers. Calculations based on the single-channel data indicated that the channels generated by HlyAΔ71–110 and HlyAΔ264–286 had a smaller size (diameter about 1.4 to 1.8 nm) than wildtype HlyA channels (diameter about 2.0 to 2.6 nm), suggesting that in these mutants part of the channel-forming domain was removed. Osmotic protection experiments with erythrocytes confirmed that HlyA, HlyAΔ71–110, and HlyAΔ264–286 form defined transmembrane pores and suggested channel diameters that largely agreed with those estimated from the single-channel data. Taken together, these results suggest that the channel-forming domain of HlyA might contain β-strands, possibly in addition to α-helical structures.
The Notch signaling pathway is crucial for mammalian heart development. It controls cell-fate decisions, coordinates patterning processes and regulates proliferation and differentiation. Critical Notch effectors are Hey bHLH transcription factors (TF) that are expressed in atrial (Hey1) and ventricular (Hey2) cardiomyocytes (CM) and in the developing endocardium (Hey1/2/L). The importance of Hey proteins for cardiac development is demonstrated by knockout (KO) mice, which suffer from lethal cardiac defects, such as ventricular septum defects (VSD), valve defects and cardiomyopathy. Despite this clear functional relevance, little is known about Hey downstream targets in the heart and the molecular mechanism by which they are regulated.
Here, I use a cell culture system with inducible Hey1, Hey2 or HeyL expression to study Hey target gene regulation in HEK293 cells, in murine embryonic stem cells (ESC) and in ESC derived CM. In HEK293 cells, I could show that genome wide binding sites largely overlap between all three Hey proteins, but HeyL has many additional binding sites that are not bound by Hey1 or Hey2. Shared binding sites are located close to transcription start sites (TSS) where Hey proteins preferentially bind to canonical E boxes, although more loosely defined modes of binding exist. Additional sites only bound by HeyL are more scattered across the genome. The ability of HeyL to bind these sites depends on the C-terminal part of the protein. Although there are genes which are differently regulated by HeyL, it is unclear whether this regulation results from binding of additional sites by HeyL.
Additionally, Hey target gene regulation was studied in ESC and differentiated CM, which are more relevant for the observed cardiac phenotypes. ESC derived CM contract in culture and are positive for typical cardiac markers by qRT PCR and staining. According to these markers differentiation is unaffected by prolonged Hey1 or Hey2 overexpression. Regulated genes are largely redundant between Hey1 and Hey2. These are mainly other TF involved in e.g. developmental processes, apoptosis, cell migration and cell cycle. Many target genes are cell type specifically regulated causing a shift in Hey repression of genes involved in cell migration in ESC to repression of genes involved in cell cycle in CM.
The number of Hey binding sites is reduced in CM and HEK293 cells compared to ESC, most likely due to more regions of dense chromatin in differentiated cells. Binding sites are enriched at the proximal promoters of down-regulated genes, compared to up-or non-regulated genes. This indicates that up-regulation primarily results from indirect effects, while down-regulation is the direct results of Hey binding to target promoters. The extent of repression generally correlates with the amount of Hey binding and subsequent recruitment of histone deacetylases (Hdac) to target promoters resulting in histone H3 deacetylation.
However, in CM the repressive effect of Hey binding on a subset of genes can be annulled, likely due to binding of cardiac specific activators like Srf, Nkx2-5 and Gata4. These factors seem not to interfere with Hey binding in CM, but they recruit histone acetylases such as p300 that may counteract Hey mediated histone H3 deacetylation. Such a scenario explains differential regulation of Hey target genes between ESC and CM resulting in gene and cell-type specific regulation.
Durch die Spleißreaktion werden nicht-kodierende Sequenzelemente (Introns) aus eukaryotischen Vorläufer-mRNAs entfernt und die kodierenden Sequenzelemente (Exons) miteinander zu einem offenen Leserahmen verbunden. Dieser zentrale Prozessierungsschritt während der eukaryotischen Genexpression wird durch das Spleißosom katalysiert, das aus den vier kleinen nukleären Ribonucleoproteinpartikeln (snRNPs) U1, U2, U4/U6 und U5, sowie einer Vielzahl weiterer Proteinfaktoren gebildet wird. Alle snRNPs besitzen eine gemeinsame ringförmige Kernstruktur, die aus sieben gemeinsamen Sm-Proteinen (SmB/B‘-D1-D2-D3-E-F-G) besteht, die ein einzelsträngiges Sequenzmotiv auf der snRNAs binden. Während sich diese, als Sm-Core-Domäne bezeichnete Struktur in vitro spontan ausbilden kann, erfolgt die Zusammenlagerung in vivo in einem assistierten und hochregulierten Prozess. Dieser ist abhängig von insgesamt mindestens 12 trans-agierenden Faktoren, die in den PRMT5- und SMN-Komplexen organisiert sind. Der PRMT5-Komplex agiert in der frühen Phase der Zusammenlagerung, indem er die Sm-Proteine durch die Untereinheit pICln rekrutiert und die symmetrische Methylierung von Argininresten in den C terminalen Schwänzen von SmB/B‘, SmD1 und SmD3 katalysiert.
Als Resultat dieser frühen Phase befinden sich die Sm-Proteine SmD1-D2-E-F-G und SmB/B‘-D3 in zwei getrennten und durch pICln organisierten Komplexen. Während SmB/B‘-D3-pICln am PRMT5-Komplex gebunden bleibt, existiert der zweite Komplex als freies Intermediat mit einem Sedimentationskoeffizienten von 6S. Diese Intermediate können nicht mit RNA assoziieren, sodass für die Fortsetzung des Zusammenlagerungsprozesses die Interaktion der Sm-Proteine mit pICln aufgelöst werden muss. Dies geschieht in der späten Phase der Sm-Core-Zusammenlagerung, in der die Sm-Proteine vom SMN-Komplex (bestehend aus SMN, Gemin2-8 und unrip) übernommen werden und pICln dissoziiert wird. Dadurch werden die Sm-Proteine für ihre Interaktion mit der snRNA aktiviert und können auf die Sm-Bindestelle transferiert werden, wodurch die Formierung des Sm-Core abgeschlossen wird.
Im Rahmen dieser Arbeit konnten mit Hilfe einer Kombination röntgenkristallographischer und elektronenmikroskopischer Methoden zwei wichtige Intermediate dieses Zusammenlagerungs-prozesses strukturbiologisch charakterisiert werden. Bei diesen Intermediaten handelt es sich um den 6S-Komplex, sowie um ein Sm-Protein-Transferintermediat mit einem Sedimentations-koeffizienten von 8S. In diesem ist der 6S-Komplex an zwei zentrale Untereinheiten des SMN-Komplexes (SMN und Gemin2) gebunden, während pICln den Komplex noch nicht verlassen hat. Der 8S-Komplex stellt daher ein „gefangenes“ Intermediat zwischen der frühen und späten Phase der Zusammenlagerung dar.
Zunächst gelang es eine erste Kristallform des rekombinant hergestellten 8S-Komplexes zu erhalten, die jedoch keine Strukturlösung erlaubte. Durch eine kombinierte Optimierung der Kristallisationsbedingung und der verwendeten Proteine wurde eine weitere ähnliche Kristallform erhalten, mit der die Kristallstruktur des 8S-Komplexes gelöst werden konnte. Die Kristallisation des 6S-Komplexes gelang im Anschluss auf Basis der Hypothese, dass Kristalle beider Komplexe aufgrund der kompositionellen Verwandtschaft zwischen 6S und 8S auch Ähnlichkeiten in der Architektur ihrer Kristallgitter aufweisen könnten. Daher wurden innerhalb von pICln gezielt Aminosäuren substituiert, die sich innerhalb von Kristallkontakten der 8S-Kristalle befanden und konformationell eingeschränkt waren. Mit entsprechend rekonstituierten 6S-Präparationen konnten dann zwei Kristallformen erzeugt werden, die eine Strukturlösung des 6S-Komplexes ermöglichten.
Durch die Kristallstruktur des 6S-Komplexes konnte für pICln eine strukturelle Mimikry der Sm-Proteine identifiziert werden. Diese ermöglicht eine Bindung der Sm-Proteine und eine frühzeitige topologische Organisation des Sm-Pentamers D1-D2-F-E-G in einer geschlossenen hexameren Ringstruktur. Die Kristallstruktur des 8S-Komplexes zeigt, wie der SMN-Komplex über Gemin2 an das Sm-Pentamer bindet. In Kombination mit einer EM-Struktur des 8S-Komplexes gelang es weiterhin, einen plausiblen Mechanismus für die Elimination von pICln und die Aktivierung der Sm-Proteine für die snRNA-Bindung zu formulieren. Somit konnten diese Arbeiten zu einem besseren Verständnis der Funktionen von trans-agierenden Faktoren bei Zusammenlagerung von RNA-Protein-Komplexen in vivo beitragen.
In mammals, KSR1 functions as an essential scaffold that coordinates the assembly of RAF/MEK/ERK complexes and regulates intracellular signal transduction upon extracellular stimulation. Aberrant activation of the equivalent MAPK signaling pathway has been implicated in multiple human cancers and some developmental disorders. The mechanism of KSR1 regulation is highly complex and involves several phosphorylation/dephosphorylation steps. In the present study, a number of novel in vivo phosphorylation sites were detected in mKSR1 by use of mass spectrometry analysis. Among others, Tyr728 was identified as a unique regulatory residue phosphorylated by LCK, a Src kinase family member. To understand how phosphorylation of Tyr728 may regulate the function of KSR1 in signal transduction and cellular processes, structural modeling and biochemical studies were integrated in this work.
Computational modeling of the mKSR1(KD) protein structure revealed strong hydrogen bonding between phospho-Tyr728 and the residues surrounding Arg649. Remarkably, this pattern was altered when Tyr728 was non-phosphorylated or substituted. As confirmed by biochemical analysis, Arg649 may serve as a major anchor point for phospho-Tyr728 in order to stabilize internal structures of KSR1. In line with the protein modeling results, mutational studies revealed that substitution of Tyr728 by phenylalanine leads to a less compact interaction between KSR1 and MEK, a facilitated KSR1/B-RAF binding and an increased phosphorylation of MEK in complex with KSR1. From these findings it can be concluded that phospho-Tyr728 is involved in tightening the KSR1/MEK interaction interface and in regulating the phosphorylation of KSR1-bound MEK by either RAF or KSR1 kinases.
Beside the Tyr728, Ser722 was identified as a novel regulatory phosphorylation site. Amino acid exchanges at the relevant position demonstrated that Ser722 regulates KSR1-bound MEK phosphorylation without affecting KSR1/MEK binding per se. Due to its localization, Ser722 might consequently control the catalytic activity of KSR1 by interfering with the access of substrate (possibly MEK) to the active site of KSR1 kinase. Together with Ser722, phosphorylated Tyr728 may further positively affect the kinase activity of KSR1 as a consequence of its vicinity to the activation and catalytic loop in the KSR1(KD). As revealed by structural modeling, phospho-Tyr728 builds a hydrogen bond with the highly conserved Lys685. Consequently, phospho-Tyr728 has a stabilizing effect on internal structures involved in the catalytic reaction and possibly enhances the phosphate transfer within the catalytic cleft in KSR1. Considering these facts, it seems very likely that the LCK-dependent phosphorylation of Tyr728 plays a crucial role in the regulation of KSR1 catalytic activity.
Results of fractionation and morphology analyses revealed that KSR1 recruits LCK to cytoskeleton for its phosphorylation at Tyr728 suggesting that this residue may regulate cytoskeleton dynamics and, consequently, cell motility. Beside that, phosphorylation of Tyr728 is involved in the regulation of cell proliferation, as shown by a significantly reduced population doubling time of KSR1-Y728F cells compared to cells expressing wild type KSR1.
Taken together, tyrosine phosphorylation in KSR1 uncovers a new link between Src family kinases and MAPK signaling. Tyr728, the novel regulatory phosphorylation site in murine KSR1, may coordinate the transition between the scaffolding and the catalytic function of KSR1 serving as a control point used to fine-tune cellular responses.
Using viruses to treat cancer is a novel approach to an age-old disease. Oncolytic viruses are native or recombinant viruses that have the innate or enhanced capability to infect tumour cells, replicate within the tumour microenvironment and subsequently lyse those cells. One representative, the vaccinia virus (VACV), belongs to the orthopoxvirus genus of the Poxviridae family. GLV-1h68, a recombinant and attenuated vaccinia virus devel- oped by the Genelux Corporation, is a member of this family currently being tested in various phase I/II clinical trials under the name GL-ONC1. It has been shown to specif- ically replicate in tumour cells while sparing healthy tissue and to metabolise prodrug at or transport immunological payloads to the site of affliction. Since imaging modalities offer little insight into viral replication deep within the body, and because oncolytic virotherapy is dependent on replication within the target tissue, the need for a monitoring system is evident. Pharmacokinetic analysis of this oncolytic agent was to give insight into the dynamics present in tumours during treatment. This, in turn, would give clinicians the opportunity to monitor the efficacy as early as possible after the onset of treatment, to observe treatment progression and possibly to gauge prognosis, without resorting to invasive procedures, e.g. biopsies. A criteria for viable biomarkers was that it had to be directly dependent on viral replica- tion. Ideally, a marker for treatment efficacy would be specific to the treatment modality, not necessarily the treatment type. Such a marker would be highly detectable (high sen- sitivity), specific for the treatment (high specificity), and present in an easily obtained specimen (blood). Taking this into consideration, the biomarkers were chosen for their potential to be indicators of viral replication. Thus, the biomarkers analysed in this thesis are: the native proteins expressed by the viral genes A27L and B5R, the virally encoded recombinant proteins β-galactosidase, β-glucuronidase, green fluorescent protein (GFP), carboxypeptidase G2 (CPG2) and carcinoembryonic antigen (CEA). Each marker is under the control of one of five different promoters present. All recombinant viruses used in this thesis express A27L, B5R, GFP and β-glucuronidase and all are derived from the parental virus GLV-1h68. In addition to these markers, GLV-1h68 expresses β-galactosidase; GLV-1h181 expresses CPG2. [...]
Pre-mRNA splicing by the spliceosome is an essential step in the maturation of nearly all human mRNAs. Mutations in six spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease characterized by progressive photoreceptor degeneration. All splicing factors linked to RP are constituents of the U4/U6.U5 tri-snRNP subunit of the spliceosome, suggesting that the compromised function of this particle may lead to RP. Here, we report the identification of the p.R192H variant of the tri-snRNP factor PRPF4 in a patient with RP. The mutation affects a highly conserved arginine residue that is crucial for PRPF4 function. Introduction of a corresponding mutation into the zebrafish homolog of PRPF4 resulted in a complete loss of function in vivo. A series of biochemical experiments suggested that p.R192H disrupts the binding interface between PRPF4 and its interactor PRPF3. This interferes with the ability of PRPF4 to integrate into the tri-snRNP, as shown in a human cell line and in zebrafish embryos. These data suggest that the p.R192H variant of PRPF4 represents a functional null allele. The resulting haploinsufficiency of PRPF4 compromises the function of the tri-snRNP, reinforcing the notion that this spliceosomal particle is of crucial importance in the physiology of the retina.